ArticleBioanalysis2026
Implementation of the fully automated diagnostic immunoanalyzer cobas e411 in the bioanalytical laboratory - Lessons learnt.
Article in Bioanalysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsThis study assessed the automated cobas e411 immunoanalyzer as a high-efficiency alternative to manual ELISA for pharmacokinetic and pharmacodynamic analyses. Key objectives included reducing manual resource burdens and minimizing analyst-dependent variability while achieving analytical performance comparable or superior to established ELISA standards. MATERIALS &
methodsTo achieve GLP and FDA 21 CFR Part 11 and 58 compliance, a dedicated "Elecsys system", comprising the off-the-shelf cobas e411 platform and an in-house developed software package (CoLiBri) for instrument control and LIMS connection was subjected to Computerized System Validation (CSV). The Elecsys system's analytical performance was compared directly to ELISA. Robustness was further assessed through clinical sample analysis and free analyte quantification in biological matrices.
resultsThe cobas e411 demonstrated comparable sensitivity and precision to ELISA while offering a significantly wider dynamic range due to electrochemiluminescence readout. Automation minimized human error and enabled high-throughput singlicate analysis, a capability unattainable with manual methods. Validation of numerous non-clinical and clinical assays and routine sample analyses confirmed platform's efficiency and ability to provide rapid turnaround for bioanalysis.
conclusionsThe Elecsys system is a robust, GLP-compliant platform that streamlines bioanalytical workflows. By automating labor-intensive steps, it significantly enhances data quality and efficiency compared to traditional manual ligand-binding assays.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.